Literature DB >> 24275954

Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy.

Jose Angel Urbano-Moral1, Ethan J Rowin, Martin S Maron, Andrew Crean, Natesa G Pandian.   

Abstract

BACKGROUND: In hypertrophic cardiomyopathy (HCM), heterogeneous myocardial hypertrophy and fibrosis are responsible for abnormalities of left ventricular (LV) function. We aimed to characterize LV global and regional myocardial mechanics in HCM, according to segmental hypertrophy and fibrosis. METHODS AND
RESULTS: Fifty-nine patients with HCM underwent standard echocardiography, 3-dimensional speckle tracking echocardiography, and cardiac magnetic resonance with late gadolinium enhancement (LGE); all 3 tests were <24 hours apart. Longitudinal, circumferential, and area strains were investigated according to the extent of LGE (no LGE, LGE<10%, and LGE≥10%), segmental thickness (≥15 versus <15 mm), and segmental LGE (LGE versus non-LGE). Attenuated global longitudinal strain showed association with extent of hypertrophy (indexed LV mass, r=0.32, P=0.01; maximum LV wall thickness, r=0.34, P=0.009; number of segments≥15 mm, r=0.44, P<0.001), whereas enhanced global circumferential strain was correlated to LV global functional parameters (indexed end-systolic volume, r=0.47, P<0.001; ejection fraction, r=-0.75, P<0.001). Parameters of global myocardial mechanics showed no association with the extent of LGE; in contrast, the extent of LGE was associated with the extent of hypertrophy. All 3 deformation parameters were attenuated both in segments≥15 mm in thickness and in those with LGE; adjusted analysis demonstrated that segmental presence of LGE was associated with additional attenuation in myocardial deformation.
CONCLUSIONS: Both hypertrophy and fibrosis contribute to regional impairment of myocardial shortening in HCM. The extent of hypertrophy is the primary factor altering global myocardial mechanics. Circumferential myocardial shortening seems to be directly involved in preservation of LV systolic performance in HCM.

Entities:  

Keywords:  cardiomyopathy, hypertrophic; echocardiography; magnetic resonance imaging

Mesh:

Substances:

Year:  2013        PMID: 24275954     DOI: 10.1161/CIRCIMAGING.113.000842

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  60 in total

1.  Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis.

Authors:  Gaetano Nucifora; Daniele Muser; Pasquale Gianfagna; Giorgio Morocutti; Alessandro Proclemer
Journal:  Int J Cardiovasc Imaging       Date:  2015-07-26       Impact factor: 2.357

2.  Left ventricular energy loss and wall shear stress assessed by vector flow mapping in patients with hypertrophic cardiomyopathy.

Authors:  Ling Ji; Wenzhi Hu; Yonghong Yong; Hongping Wu; Lei Zhou; Di Xu
Journal:  Int J Cardiovasc Imaging       Date:  2018-04-06       Impact factor: 2.357

Review 3.  Strain, strain rate, torsion, and twist: echocardiographic evaluation.

Authors:  Anders Opdahl; Thomas Helle-Valle; Helge Skulstad; Otto A Smiseth
Journal:  Curr Cardiol Rep       Date:  2015-03       Impact factor: 2.931

4.  Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease.

Authors:  Brendan N Putko; Haran Yogasundaram; Kelvin Chow; Joseph Pagano; Aneal Khan; D Ian Paterson; Richard B Thompson; Gavin Y Oudit
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-03-06       Impact factor: 6.875

5.  Global cardiac alterations detected by speckle-tracking echocardiography in Fabry disease: left ventricular, right ventricular, and left atrial dysfunction are common and linked to worse symptomatic status.

Authors:  Daniel A Morris; Daniela Blaschke; Sima Canaan-Kühl; Alice Krebs; Gesine Knobloch; Thula C Walter; Wilhelm Haverkamp
Journal:  Int J Cardiovasc Imaging       Date:  2014-10-15       Impact factor: 2.357

6.  The prognostic value of standardized reference values for speckle-tracking global longitudinal strain in hypertrophic cardiomyopathy.

Authors:  Gregory R Hartlage; Jonathan H Kim; Patrick T Strickland; Alan C Cheng; Nima Ghasemzadeh; Maria A Pernetz; Stephen D Clements; B Robinson Williams
Journal:  Int J Cardiovasc Imaging       Date:  2015-01-14       Impact factor: 2.357

7.  Two-dimensional and three-dimensional left ventricular deformation analysis: a study in competitive athletes.

Authors:  Flavio D'Ascenzi; Marco Solari; Michele Mazzolai; Matteo Cameli; Matteo Lisi; Valentina Andrei; Marta Focardi; Marco Bonifazi; Sergio Mondillo
Journal:  Int J Cardiovasc Imaging       Date:  2016-08-13       Impact factor: 2.357

8.  Characteristic systolic waveform of left ventricular longitudinal strain rate in patients with hypertrophic cardiomyopathy.

Authors:  Kazunori Okada; Sanae Kaga; Taisei Mikami; Nobuo Masauzi; Ayumu Abe; Masahiro Nakabachi; Shinobu Yokoyama; Hisao Nishino; Ayako Ichikawa; Mutsumi Nishida; Daisuke Murai; Taichi Hayashi; Chikara Shimizu; Hiroyuki Iwano; Satoshi Yamada; Hiroyuki Tsutsui
Journal:  Heart Vessels       Date:  2016-10-18       Impact factor: 2.037

9.  Ultrasonic Assessment of Myocardial Microstructure in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy.

Authors:  Pranoti Hiremath; Patrick R Lawler; Jennifer E Ho; Andrew W Correia; Siddique A Abbasi; Raymond Y Kwong; Michael Jerosch-Herold; Carolyn Y Ho; Susan Cheng
Journal:  Circ Heart Fail       Date:  2016-09       Impact factor: 8.790

10.  Quantitative diffusion-weighted magnetic resonance imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy compared with T1 mapping.

Authors:  Lian-Ming Wu; Bing-Hua Chen; Qiu-Ying Yao; Yang-Rongzheng Ou; Rui Wu; Meng Jiang; Jiani Hu; Dong-Aolei An; Jian-Rong Xu
Journal:  Int J Cardiovasc Imaging       Date:  2016-05-19       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.